In Vivo (Add solvents to the product individually and in order.)
Homogeneous suspension
CMC-NA
≥5mg/ml
Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution
2%DMSO
20%PEG300
5%Tween80
73%ddH2O
Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.
0.900mg/ml
(1.93mM)
Taking the 1 mL working solution as an example, add 20 μL of 45 mg/ml clarified DMSO stock solution to 200 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 730 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
Biological Activity
Description
TRC051384 is an inducer of heat shock protein 70 (HSP70) and a potent anti-inflammatory agent.
Targets
HSP70
In vitro
TRC051384 is a compound that induces HSPA1A/B expression and subsequent Hsp70 production via heat shock factor-1 (HSF1) activation. This compound increases HSP70B mRNA expression in both HeLa and primary mixed neuronal cells. Induction of HSP70 by this chemical involves HSF1 activation and results in elevated chaperone and anti-inflammatory activity.
In Vivo
Treatment with TRC051384 significantly reduces stroke associated neuronal injury and disability in a rat model of transient ischemic stroke even when administered 8 hours post onset of ischemia. This compound significantly reduces infarct size, brain oedema and improves neurological deficit. It delays thrombus formation in WT mice, the tail bleeding time still being unaltered.
Induction of HSP70B mRNA is carried out by treatment of cells with TRC051384 (6.25 and 12.5 μM) for 4 hours duration for HeLa cell line and total RNA is isolated. For all RNA samples, cDNAs are synthesized and expression of HSP70B mRNA along with expression of 18S rRNA is monitored by real-time PCR employing ABI 7000 system.
Sellecks TRC051384 Has Been Cited by 3 Publications
HSP70 attenuates compression-induced apoptosis of nucleus pulposus cells by suppressing mitochondrial fission via upregulating the expression of SIRT3
[ Exp Mol Med, 2022, 10.1038/s12276-022-00745-9]
HSP90 Inhibitor 17-AAG Attenuates Nucleus Pulposus Inflammation and Catabolism Induced by M1-Polarized Macrophages
[ Front Cell Dev Biol, 2021, 9:796974]
Activation of HSP70 impedes tert-butyl hydroperoxide (t-BHP)-induced apoptosis and senescence of human nucleus pulposus stem cells via inhibiting the JNK/c-Jun pathway
[ Mol Cell Biochem, 2021, 10.1007/s11010-021-04052-1]
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.
